Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RZL-012 Second Treatment for Submental Fat
NCT05763160Phase 2Completed
- Sponsor
- Raziel Therapeutics
- Start
- May 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Tapencarium in submental fat, sponsored by Raziel Therapeutics. Primary endpoint: Adverse events follow up at 84 days. Started May 2023; status: completed.
02
Drugs
Tapencarium
03
Conditions
submental fat
Beyond the preview
Go deeper on NCT05763160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05763160.